

IMPORTANT INFORMATION FROM CIGNA

COVID-19 public health emergency period extended through January 15, 2022

Since the COVID-19 pandemic began, Cigna has taken important steps to deliver timely accommodations to providers and customers, helping to ensure that customers have continued access to COVID-19 screening, testing, and treatment in safe settings.

Extension of key accommodations

- To align with the recent [extension](#) of the federal public health emergency (PHE) period, Cigna is again extending the cost-share waiver for COVID-19 testing and testing-related services through January 15, 2022.
- Cigna's interim credentialing accommodations are extended through December 31, 2021.
- Cigna's COVID-related accommodations for virtual care continue to remain in effect until further notice.
- Cigna's facility-to-facility transfer authorization waiver ended on October 18, 2021. However, Cigna will not enforce an administrative denial for failure to secure authorization on appeal if an extenuating circumstance due to COVID-19 applied (e.g., bed capacity or staffing issues).

How Cigna covers vaccine administration

After the emergency use authorization (EUA) or approval of each COVID-19 vaccine by the FDA, CMS will identify the specific vaccine code(s) along with the specific administration code(s) for each vaccine.

As a reminder, we reimburse the administration of all FDA and EUA-approved COVID-19 vaccines at the [established national CMS rates](#) when claims are billed under the medical benefit. This guidance will also apply to any additional vaccines that receive EUA approval, including new booster doses and pediatric vaccines.

Get the latest updates

We updated our dedicated [COVID-19 provider web page](#) on October 22, 2021 to highlight the latest updates. We encourage you to visit the site to get these updates and more.

Thank you again for the quality care you provide and for all that you're doing to help our customers.

Visit [CignaforHCP.com](https://www.cigna.com/forHCP)